Laboratory

Discover our products

Clinical

Discovers our solutions

ABL acquires CDL Pharma to develop CRO-related services and assays manufacturing capacity

Jul 05, 2018

We are delighted to announce you that Advanced Biological Laboratories (ABL – https://www.ablsa.com) has just signed a definitive agreement to acquire CDL Pharma (http://www.cdlpharma.com/), a company headquartered in France – see the full press release. CDL Pharma Provides comprehensive biolo…
Read more
VHIR will collaborate with ABL laboratories in developing software tools

Jul 03, 2018

This June, the Consorcio Centro de Investigación Biomédica en Red, M.P. – CIBER, the Advanced Biological Laboratories S.A. – ABL and the Vall d’Hebron Research Institute – VHIR have signed a collaboration agreement to develop an analysis software for the high resolution subtyped results obtained on…
ABL and Seha Connect IT Solutions LLC enter into an exclusive distribution agreement

May 30, 2018

Advanced Biological Laboratories S.A. and Seha Connect IT Solutions LLC enter into an exclusive distribution and development collaboration agreement covering 14 countries in the Middle East region. The agreement is effective immediately and covers a large panel of clinical software developed by ABL…
Read more

ABL Announces Distribution Agreement with ROCHEM BIOCARE in Panama

Apr 12, 2018

Advanced Biological Laboratories (ABL) S.A. and ROCHEM BIOCARE DE PANAMA, S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Panama. See current channel partners.
Read more
ABL Announces Distribution Agreement with Laborama Ltd. in Lithuania

Apr 05, 2018

Advanced Biological Laboratories (ABL) S.A. and Laborama Ltd. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Lithuania. See current channel partners.
Read more
Immediate Availability of New DeepChek Assays for Cytomegalovirus (CMV) and Mycobacterium tuberculosis (TB) Drug Resistance

Mar 27, 2018

ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for: Determining antiviral drug resistance to cidofovir, foscarnet sodium, ganciclovir and maribavir in patients infected with cytomegalovirus (CMV) – DEEPCHEK®-CMV UL54/UL97 ASSAY Determining dr…
Read more

ABL and Thermo Fisher Scientific Corporation Ink Supply Agreement on Capillary Electrophoresis Instruments

Jan 22, 2018

ABL and Thermo Fisher Scientific Corporation are pleased to announce the execution of a supply agreement conferring to ABL the ability to combine Thermo Fisher Scientific Corporation’s Genetic Analyzers (3500 Genetic Analyzer, Applied Biosystem SeqStudio Genetic Analyzer…) with its DeepC…
Read more
ABL-EVIVAR Obtains New Patent Allowance on Hepatitis B Virus Polymerase Gene

Dec 19, 2017

ABL is pleased to announce the allowance of a new patent covering new Hepatitis B primers and kits hybridizing to DNA or mRNA of the Hepatitis B Virus Polymerase gene.
Read more
DeepChek®-HIV RT/PROT and DeepChek®-HIV INT Genotyping Assays Successfully Passed 2016 National Quality Control Program with 100% Accuracy.

Sep 19, 2017

We are pleased to announce that the DeepChek®-HIV RT/PROT assay and the DeepChek®-HIV INT assay successfully passed a national and independent quality control program in France and Switzerland and obtained 100% positive results on sensibility, 100% on specificity and also 100% on scoring on HIV geno…
Read more